RMD Dec 2024 180.000 call
| Previous close | 46.58 |
| Open | 24.20 |
| Bid | 42.90 |
| Ask | 44.70 |
| Strike | 180.00 |
| Expiry date | 2024-12-20 |
| Day's range | 24.20 - 46.58 |
| Contract range | N/A |
| Volume | |
| Open interest | 55 |
GlobeNewswireDeveloped in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA)Prevalence of OSA in the United States expected to increase 26.7% in men and women aged 30 –70Real-world trends of glucagon-like peptide-1 (GLP-1) receptor agonist and PAP therapy use show patients who were adherent to their GLP-1 medication had higher levels of PAP therapy use than those
ZacksHere's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
ZacksCVS Health (CVS) Expands Food and Beverage Line With New Launch
CVS Health's (CVS) Well Market brand offers a blend of mouthwatering flavors and nutritious options, expertly crafted and taste-tested by food enthusiasts.
